In the News

Combined FIT, H. pylori testing not linked with lower gastric cancer mortality

Inviting patients to get both Helicobacter pylori stool antigen testing and a fecal immunochemical test (FIT) was associated with lower gastric cancer incidence than FIT alone after adjustment, but no change in related mortality, according to a Taiwanese trial.

AI-assisted colonoscopy does not improve detection of advanced neoplasias

While colonoscopies with artificial intelligence (AI) assistance yielded more adenomas compared with conventional colonoscopy, rates of advanced neoplasias per colonoscopy did not differ, a systematic review and meta-analysis found.

Elimination diets, PPIs most cost-effective for EoE treatment

Elimination diets were the most cost-effective strategy for treatment of eosinophilic esophagitis (EoE) over a five-year period, while proton-pump inhibitors (PPIs) were the most cost-effective first-line drugs, a recent study found.

MKSAP Quiz: Treatment of HCV

A 58-year-old woman is evaluated for treatment of hepatitis C virus (HCV) infection. She has unresectable metastatic pancreatic adenocarcinoma. She requests treatment of her HCV infection. What is the most appropriate management?

Spotlight on factors in ulcerative colitis severity

An analysis of patients who had been hospitalized for acute severe ulcerative colitis found certain factors at admission predicted need for colectomy within a year, and a Danish genetic study identified a specific allele tied to severe ulcerative colitis.

FIT test completion, yield similar among patients 45 to 49 years and 50-year-olds

In a study of patients completing their first fecal immunochemical test (FIT), those ages 45 to 49 years had a lower adenoma detection rate but a similar rate of colorectal cancer as patients who were 50 years of age when they first underwent screening.

Case report covers autoimmune ascites

The rare case occurred in a 72-year-old woman.

Spotlight on liver health in diabetes

A review compared liver outcomes for most classes of diabetes drugs, while a retrospective study looked at glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors head to head. Another study offered a new score for metabolic dysfunction-associated steatotic liver disease.

In patients receiving invasive ventilation, PPIs reduce upper GI bleeding but did not affect mortality at 90 d

An ACP Journal Club commentary said the results of the REVISE trial support the routine use of first-line proton-pump inhibitors (PPIs) for stress ulcer prophylaxis in high-risk, critically ill, ventilated patients but noted that the definition of “high risk” is uncertain.